JADELLE

This brand name is authorized in Ecuador, Finland, Mexico, New Zealand, Nigeria, South Africa.

Active ingredients

The drug JADELLE contains one active pharmaceutical ingredient (API):

1	Levonorgestrel UNII 5W7SIA7YZW - LEVONORGESTREL
	The precise mode of action of levonorgestrel as an emergency contraceptive is not known. At the recommended regimen, levonorgestrel is thought to work mainly by preventing ovulation and fertilisation if intercourse has taken place in the preovulatory phase, when the likelihood of fertilisation is the highest.
	Read more about Levonorgestrel

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JADELLE Implant	MPI, EU: SmPC	Medicines and Medical Devices Safety Authority (NZ)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
G03AC03	Levonorgestrel	G Genito urinary system and sex hormones → G03 Sex hormones and modulators of the genital system → G03A Hormonal contraceptives for systemic use → G03AC Progestogens
Discover more medicines within G03AC03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EC	Agencia Nacional de Regulación, Control y Vigilancia Sanitaria	360590612
FI	Lääkealan turvallisuus- ja kehittämiskeskus	011521, 445346
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	044M2011
NG	Registered Drug Product Database	04-3559
Switch country to Nigeria in order to find specific presentations of JADELLE
NZ	Medicines and Medical Devices Safety Authority	11260
ZA	Health Products Regulatory Authority	A40/18.1/0138